Lumida
/BLFS
⌘K
BioLife Solutions Inc

BioLife Solutions Inc

BLFS
$29.15USD↓-3.67%-1.11 today

MARKET CAP

1.4B

P/E (TTM)

121.5x

FWD P/E

103.0x

DAY RANGE

$29 – $31

52W RANGE

$18
$31

AI Summary

Stalk
StalkMedium

BLFS remains in a Stage 2 advancing uptrend with bullish medium-term momentum, but recent rejection at the key resistance zone and overbought conditions have led to short-term exhaustion. Price is extended above rising EMAs and rejected at the highs. Execution is deferred until a pullback into the rising EMA support zone or prior breakout levels is absorbed, providing a higher-probability entry.

  • ↑Q1 2026 revenue reached $27.5 M, up 25% YoY on strong biopreservation media demand
  • ↑Adjusted EBITDA margin widened to 22%, reflecting scalable operational leverage
  • ↓Top 20 customers generate 80% of BPM revenue, raising concentration risk
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

BioLife Solutions, Inc. (NASDAQ: BLFS) is a leading provider of biopreservation products and services for the cell and gene therapy (CGT) market. The company specializes in biopreservation media and related technologies essential for the preservation and transport of cell and gene therapies. Given the rapid growth of the CGT space and increasing demand for sophisticated therapeutic solutions, BioLife holds a strong position as a key player, boasting a substantial market share with over 85% of total revenue derived from biopreservation media.

Bull says

  • ↑Q1 2026 revenue reached $27.5 M, up 25% YoY on strong biopreservation media demand
  • ↑Adjusted EBITDA margin widened to 22%, reflecting scalable operational leverage
  • ↑2026 revenue guidance of $112.5–$115 M implies 17–20% growth
  • ↑BPM products used in 250+ CGT trials, including 17 approved therapies
  • ↑Panthera CryoSolutions acquisition expands cryopreservation portfolio for long-term growth
  • ↑Strong earnings revisions, high earnings yield, solid profitability and liquidity support valuation

Bear says

  • ↓Top 20 customers generate 80% of BPM revenue, raising concentration risk
  • ↓High leverage elevates balance-sheet strain; minimal dividend yield reduces income appeal
  • ↓Elevated stock volatility and competitive pricing pressure margin stability
  • ↓Gross margin hit by shift toward lower-margin bag products
  • ↓Recent analyst downgrades signal potential sentiment headwinds
  • ↓Low institutional ownership and weak dividend profile reflect risk-averse sentiment

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-17-2026bullish

Transcript signals

Bull points

  • We entered 2026 with a simplified business and heightened focus on high margin recurring revenue and our results this quarter demonstrate the operating leverage in our model as a result.
  • At the same time, we're seeing continued momentum across the CGT landscape driven by expansion into larger indications, encouraging data readouts, strategic M&A, and an approving funding environment, all of which we believe will support long-term growth across our end markets and underpin sustained value creation for BioLife shareholders.
  • total revenue reached $27.5 million, increasing 25% year-over-year.

Bear points

  • Gross margin and adjusted EBITDA as a percent of revenue declined year over year due to the previously discussed bag yield dynamics.
  • I think we're still a couple of years out. But, you know, Allogene has published some decent data. I think they did a raise. So from a financial perspective, they're in a much more solid position. And I think they're, although the overall BPM volumes per patient might be a little bit lower, the opportunity to address much larger patient populations is, in our estimation, going to far outweigh the reduced amount of volume per patient. But again, I think it's a good two-plus years away from really having a revenue impact on BioLife.
  • Not that will directly impact our revenue in any way, no.
Read full transcript analysis ›